

# Programme

## Thursday, 23 October 2014

### 14.30 - 15.00 Opening and welcome

#### Video intro - Swedish Drug User Union

Dr. Ingo Michels, Head of Unit,  
Office of the Federal Drug Commissioner of Germany

Marco Jesse, JES Bundesverband

Chair: Eberhard Schatz,  
Correlation Network, Amsterdam

### 15.00 - 15.30 Keynote speech

#### Hepatitis C and Drug Use - turn the page

Dr. med. Jörg Götz, Berlin

### 15.30 - 16.00 Coffee break

### 16.00 - 17.00 3 national examples of hepatitis policies: Policy-maker - drug user representative

#### Scotland:

Nicola Rowan, National Coordinator for Viral Hepatitis,  
Scottish Government  
Tony Cassidy, Scottish Drug User Representative

#### France

Prof Daniel Dhumeaux, University of Paris-Est  
Miguel Velazquez Gorsse, president ASUD

#### Germany

Dr. Ingo Michels, Head of Unit, Office of the Federal Drug  
Commissioner  
Dirk Schäffer, European Network of People Who Use Drugs,  
Deutsche Aids Hilfe

Moderator: Prof. Heino Stöver,  
University of Applied Sciences, Frankfurt

# Thursday, 23 October 2014

**17.00 - 18.30 What do we want for the future:  
Presenting the Manifesto / Berlin Declaration:**

## **7 stakeholders for the 7 key messages for a better hepatitis C policy and practice:**

Moderator: Jose Queiroz, Apdes, Porto

- 1. Scale Up Harm Reduction Community Based Programmes:**  
Maria Phelan, Harm Reduction International (HRI)
- 2. Access to HCV Testing, Treatment and Care Services**  
Prof. Mojca Maticic, Clinic for Infectious Diseases and Febrile Illnesses University Medical Centre Ljubljana
- 3. Access to Affordable HCV Treatments**  
Anya Sarang, Andrey Rylkov Foundation, Moscow
- 4. Decriminalisation of People Who Use Drugs**  
Christopher Hallam, International Drug Policy Consortium
- 5. Meaningful Involvement of High Risk Communities**  
Efi Kokkini, European Network of People Who Use Drugs
- 6. Improved HCV and Health Literacy**  
Magdalena Harris, PHD, Centre of Research on Drugs and Health Behaviour, London School of Hygiene and Tropical Medicine
- 7. Effective Targeted HCV Strategies and Action Plans**  
Achim Kautz, European Liver Patient Association (ELPA)

**18.30 Reception and buffet**

# Friday, 24 October 2014

Major session (MS)

Workshop (WS)

Parallell session (PS)

**09.00 - 10.30**

## Access to hepatitis C treatment in Europe and abroad - the politics on pricing

Chair: Azzi Momenghalibaf, Open Society Foundation

This session aims to unpack and explore the controversy around affordability and access to new hepatitis C treatments in both wealthy and middle-income countries through a moderated multi-stakeholder panel discussion that includes patient advocates and policy makers.

Speakers:

Luis Mendao, European Aids Treatment Group

Chloe Forette, Medicine du Monde

Paata Sabelashvili, Georgian Harm Reduction Network

Gaëlle Krikorian, Advisor on Intellectual Property and Access to Knowledge, Green Party in the EP

Ricardo Bapista Leite, MP Portugal

**10.30 - 11.00 Coffee break**

**11.00 - 12.30**

Chair:  
Dagmar Hedrich,  
EMCDDA

### HCV treatment and care - the way forward

Amber Arain - Treatment efficiency and safety results of first generation DAA-based regimes **A1**

Chis Ford - Integrated care for the treatment of Hepatitis C: Ways of improving access to treatment **A2**

Magdalena Harris - 'Treatment as prevention' for hepatitis C: What does this mean for people who inject drugs? **A3**

Chair:  
Katrin Schiffer,  
Correlation

### HCV in migrants en MSM - challenges and responses

Fred Bladou - SLAM - Drugs by injection in the gay community in a sexual context **A4**

Mick Quinlan - Hepatitis C and MSM in Ireland – a need for awareness? **A5**

Luis Mendao - HCV and HIV community testing and linkage to care for migrants **A6**

Chair:  
Angelos Hazakis,  
Hep B & C Policy  
Association

### HCV in prison settings

Vic Arendt - High recurrence rate of Hepatitis c infection after treatment in prison **A7**

Heino Stöver - Epidemiology and Prevention of HCV in Prisons **A8**

Discussion: Recommendations regarding hepatitis C prevention, screening and treatment in prisons **A9**

### Workshop W1 Demonstration of FibroScan® testing

Dr. Elisabeth Avril, Assoc. Gaia, Paris

The mobile FibroScan® : An innovative project of hepatitis screening among people who use drugs in „Ile-de-France“ (Paris region) incl. a FibroScan® demonstration **A10**

### Workshop W2 How to create impact on policy making for HCV?

Jose Queiroz, Apdes

The workshop will present shortly the Policy and Advocacy strategy developed, establishing bridges with the national realities and reflecting about practical examples. It aims to prepare the field for a sustainable platform in the field of hepatitis C and drug use **A11**

# Friday, 24 October 2014

**12.30 - 14.00 Lunch**

**14.00 - 15.30**

|   |  |  |   |
|---|--|--|---|
| <p>Chair:<br/>Achim Kautz, ELPA</p> <p><b>Hepatitis C testing and treatment barriers among active drug users</b></p>  | <p>Chair:<br/>Berne Stralenkrantz,<br/>EuroNPUD</p> <p><b>Drug User Driven Session</b></p>   | <p>Chair:<br/>John Peter Kools,<br/>Correlation Network</p> <p><b>Hep C policy between negligence and adaption: Ukraine, Russia and European Union</b></p>   | <p>Chair:<br/>Mika Mikkonen, A klinikka</p> <p><b>Reach out to patient groups - what works and what not</b></p>   |
| <p>Heike Zurhold - Hepatitis C testing and treatment barriers among active drug users in European cities <a href="#">A12</a></p> <p>Ruth Zimmermann - Hepatitis C testing and treatment barriers among active drug users in Germany – results from the DRUCK-study <a href="#">A13</a></p> <p>Marie Jauffret-Roustide - Rapid testing and access to HCV treatment among drug users – paradoxical perceptions of health professionals. Results of “ANRS-Cube” research <a href="#">A14</a></p> | <p>Miguel Velazquez Gorsse - ASUD’s experience: 20 years of peer-to-peer-work to become aware of Hep C <a href="#">A15</a></p> <p>Maria Teresa Ninni - HCV Peer Support: the alliance between practical experiences and professional knowledge <a href="#">A16</a></p> <p>Discussion<br/>The Swedish Drug User Union: Liver or die ! <a href="#">A17</a></p> | <p>Anya Sarang - Hepatitis C in Russia: an epidemic of negligence <a href="#">A18</a></p> <p>Ludmila Maistat- Scaling up access to HCV treatment for PWID’s in Ukraine <a href="#">A19</a></p> <p>Mojca Maticic - Strategies for treatment of hepatitis C in Europe: an overview <a href="#">A20</a></p> | <p>Marie Debrus - Experience from an Innovative community-based educational intervention among active injecting drug users <a href="#">A21</a></p> <p>Agnes van der Poel - Case finding and treatment of HCV in addiction care <a href="#">A22</a></p> <p>Alexander Würfel - Lasting improvement in the level of care for patients on substitution treatment with hepatitis C – experiences of AbbVie Germany <a href="#">A23</a></p> <p><b>Workshop: W3<br/>HCV prevention skills</b><br/>Trainer: Danny Morris, Andrew Preston<br/>Topics to be addressed: strategies to reduce accidental sharing; the role of foil provision; increasing NPS coverage <a href="#">A24</a></p> |

**15.30 - 16.00 Coffee break**

**16.00 - 17.00 The future of HCV treatment and policy: what’s next**

Chair: Jeff Lazarus, Rigshospitalet, University of Copenhagen

**The closing plenary brings together European hepatitis experts from an array of settings to discuss the future of hepatitis C treatment in Europe and abroad. And what we should do about it**

Discussion with the audience

**17.00 Closing**